恩帕格利弗洛辛减少左心室质量增加,改善心肌细胞缩
Xin Chen1, Christian T Wohnhaas2, Denis Delić3
1Institute for Clinical Research and Systems Medicine, Health and Medical University, Potsdam, Germany; Fifth Department of Medicine (Nephrology/Endocrinology/Rheumatology/Pneumology), University Medical Centre Mannheim, University of Heidelberg, Germany; The First Clinical Medical College of Jinan University, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
|August 29, 2025
概括
在心综合征小鼠模型中,恩帕格利弗洛辛有效降低左心室缩和心肌细胞扩大. 这些好处与参与心脏发育和重塑的调节基因有关.
科学领域:
- 心脏病学
- 肝脏病学
- 药理学
背景情况:
- 左心室缩 (LVH) 是心综合征的一个常见并发症.
- 恩帕格利弗洛辛具有心脏保护作用,可能通过减少左心室质量 (LVM).
研究的目的:
- 在非糖尿病心脏病综合征模型中研究Empagliflozin对LVH的影响.
- 探索Empagliflozin心脏保护作用的分子机制.
主要方法:
- 使用5/6切除小鼠模型诱导心综合征.
- 随后通过心声学,组织学,snRNA-seq和qRT-PCR对心脏结构,功能和分子变化的评估进行.
主要成果:
- 恩帕格利弗洛辛治疗显著降低了LVM和心肌细胞缩,与特尔米萨坦相比.
- 在使用Empagliflozin时,snRNA- seq检测出心肌细胞发育基因 (Fhl2,Tbx20,Angpt1) 的差异表达.
- 恩帕格利弗洛辛增加了Fhl2表达和减少了Tbx20表达,这表明心脏重塑的调节.
结论:
- 在心综合征模型中,Empagliflozin可以减轻LVH和心肌细胞缩.
- 通过调节参与心肌细胞发育和心肌重塑的基因来调节心脏保护作用.
- 这些发现支持Empagliflozin在治疗心脏脏综合征相关的心脏并发症方面的潜力.
相关概念视频
01:29Heart Failure II: Pathophysiology
37
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
37
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23